Immune-boosted boron neutron capture therapy shows striking tumor targeting in early study

A new cancer treatment concept called iBNCT, short for immune-enhanced boron neutron capture therapy, has been presented in a peer-reviewed, accepted manuscript published in Cancer Nanotechnology. The approach combines three strategies that are usually deployed separately: tumor-targeted drug delivery, radiotherapy and immunotherapy. The authors describe it as a way to pack the benefits of multi-course treatment regimens into a single intervention with short treatment time and low cost.

The work addresses a persistent problem in oncology. Despite recent progress, the 5-year survival rates for many types of cancer remain below 30 percent, and current modalities are limited by systemic toxicity, low efficacy and lack of long-term sustainability. Physicians often resort to combinations such as chemotherapy followed by surgical resection and then immunotherapy, which requires many courses of treatment, elongated inpatient care and high cost.

In the iBNCT design, sustained-release boron-10 drugs are formulated together with an immune cell adjuvant and delivered directly into tumors using microneedle jet injection devices.

Pharmacokinetics data reported in the study revealed what the authors call a reversed boron-10 distribution, with a high concentration in tumors and a low concentration in blood and main organs. A one-time delivery of 30 mg of boron-10 per kilogram led to an intratumor boron-10 concentration of over 300 ppm within a 24-hour window, and a tumor-to-normal ratio of up to 4000.

Upon neutron irradiation, a model-estimated tumor cell killing rate of 99.6 percent was achieved. It is important to note that this figure is a model estimate rather than a directly measured clinical outcome, and the study is at a preclinical stage of development.

According to the authors, the in-situ formed neoantigens, with stimulation from the immune cell adjuvant, triggered a very strong adaptive immune response and produced a high level of tumor antigen-specific T cells in a controllable fashion. The high intratumor boron-10 concentration along with the exceptional tumor-to-normal ratio provides the basis for effective tumor cell killing, reduces the requirement for high neutron flux, and significantly improves irradiation safety with less burden on in-person radioactive protection.

The researchers also propose that the in-situ generated tumor antigen-specific T cells could be collected, amplified and infused back into patients, providing an observable anti-tumor immune memory.

The authors believe that iBNCT, with its short treatment time and low cost, could potentially become a cancer therapeutic modality that replaces current combination therapeutic strategies.

Readers should interpret the reported results with appropriate care: the pharmacokinetics and cell-killing figures come from the authors’ own preclinical measurements and models, and the immune-memory and clinical-replacement claims are forward-looking statements by the research team rather than demonstrated patient outcomes.

Subject of Research: Immune-enhanced boron neutron capture therapy combining targeted boron-10 delivery with an immune adjuvant for cancer treatment

Article Title: Targeted delivery of boron depots containing immune adjuvant to achieve efficient cancer therapy via a combination of BNCT and cancer vaccine

Article References: Mao, S., Hu, H., Long, L., Wang, J., Wan, H., Lv, J., Wang, Y., Xie, L., Shao, Z., & Huang, S. (2026). Targeted delivery of boron depots containing immune adjuvant to achieve efficient cancer therapy via a combination of BNCT and cancer vaccine. Cancer Nanotechnology. https://doi.org/10.1186/s12645-026-00438-2

Image Credits: AI Generated

DOI: 10.1186/s12645-026-00438-2

Keywords: boron neutron capture therapy, BNCT, cancer nanotechnology, boron-10, immune adjuvant, cancer vaccine, microneedle jet injection, tumor targeting, radiotherapy, immunotherapy, preclinical study, neoantigens